Harvest Bitcoin Spot ETF
03439
Bosera HashKey Bitcoin ETF
03008
ChinaAMC Bitcoin ETF
03042
CSOP Bitcoin Futures ETF
03066
Samsung Bitcoin Futures Active ETF
03135
HK Stock MarketDetailed Quotes
01530 3SBIO
- 6.350
- +0.030+0.47%
Not Open Dec 4 16:08 CST
15.21BMarket Cap8.37P/E (TTM)
6.460High6.270Low21.46MVolume6.390Open6.320Pre Close136.65MTurnover0.90%Turnover Ratio8.89P/E (Static)2.40BShares7.85052wk High0.97P/B15.21BFloat Cap4.66052wk Low0.25Dividend TTM2.40BShs Float22.632Historical High0.250Dividend LFY3.01%Amplitude4.170Historical Low6.367Avg Price500Lot Size3.94%Div YieldTTM3.94%Div Yield LFY
3SBIO News
[Brokerage Focus] CICC Securities: Several heavyweight domestically produced innovative drugs included in medical insurance, fund revenue and expenditure expected to improve.
Jingu Financial News | CMB International released a research report, stating that the MSCI Chinese medical index has cumulatively fallen by 17.6% since the beginning of the year, underperforming the MSCI China index by 30.1%. Benefiting from overseas interest rate cuts and domestic macroeconomic improvements, the medical industry, as a high elasticity sector, is expected to outperform the market. The new version of the medical insurance catalogue has been announced, with multiple heavyweight domestic innovative drugs included. The bank expects the price reduction of renewed varieties to be moderate, reflecting the strong support of the medical insurance fund for innovative drugs. In September and October this year, the balance of basic medical insurance (centralized fund) has significantly improved. As the policy focus shifts to stimulating the economy, the bank believes that the financial status of the medical insurance fund is
Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
China Merchants: Maintains a "shareholding" rating on 3SBio (01530) with target price raised to HK$11.
China Merchants expects 3sbio to continue achieving double-digit total revenue growth in the 2025 and 2026 fiscal years.
China Securities Co.,Ltd.: In the 2024 version of the medical insurance catalog, the number of innovative drugs added has reached a new high, balancing 'ensuring basic coverage' and 'supporting genuine innovation'.
Overall situation of the 2024 medical insurance catalog: the results are stable, meeting expectations, with a record high in the number of new innovative drugs, reflecting a balanced consideration of fund safety, public medical needs, and support for innovation.
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Hong Kong stocks are moving differently | Most pharmaceutical stocks are rising as the results of the medical insurance negotiations are about to be revealed. Institutions indicate that the sector still has further room for recovery.
Most pharmaceutical stocks are rising, as of the deadline, Keji Pharmaceutical-B (02171) rose by 12.38%, to 7.71 Hong Kong dollars; innocare (09969) rose by 5.36%, to 6.49 Hong Kong dollars; Kainuo Ya-B (02162) rose by 4.3%, to 41.25 Hong Kong dollars.
3SBio's Unit Gets Exclusive Commercialization Rights for Clifutinib Besylate in Mainland China
3SBio Partners With Sunshine Lake Pharma for Drug Rights
3sbio (01530.HK): Shenyang 3sbio and guangdong hec technology holding reached a cooperation on sulfonamic acid clifene.
Gelonghui November 25th | 3sbio (01530.HK) announced that its subsidiary Shenyang 3sbio Pharmaceutical Co., Ltd. has reached a cooperation agreement with Guangdong Hec CJ Pharm Co., Ltd. and its subsidiary Yichang Hec CJ Pharm Co., Ltd. on the commercialization of specific indications of Benzoate Crizotinib. According to the agreement, Shenyang 3sbio will obtain the exclusive commercialization rights of Crizotinib specific indications under the product portfolio of Guangdong Hec CJ Pharm in mainland China. Shenyang 3sbio will make the initial payment and corresponding R&D and sales milestone payments to Guangdong Hec CJ Pharm as agreed in the agreement. Guangdong Hec CJ Pharm will continue to be responsible for the Crizotinib
Express News | 3Sbio - Cooperation Between Shenyang Sunshine and Sunshine Lake Pharma in Respect of Clifutinib Besylate
3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet
Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.
①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
3SBio's Mandi Shines in 2024 Double 11 Sales
3SBio CFO Boosts Shareholding, Confident in Future
The chief financial officer of 3sbio, He Xiang, increased his shareholding by a total of 3 million shares.
Gelonghui, November 14th | 3sbio (01530.HK) announced that it recently received a report from the company's chief financial officer, Mr. He Xiang, stating that from January 1, 2024, to the date of this announcement, he has cumulatively increased his shareholding in the company by purchasing a total of 3 million ordinary shares through centralized bidding at an average price of approximately HKD 5.99 per share, accounting for about 0.12% of the total issued shares. Mr. He indicated to the board of directors that he believes the shares are undervalued in the long term and, based on his long-term confidence in the company's business and prospects, he will consider increasing his shareholding further depending on market conditions and subject to applicable laws and regulatory provisions.
3sbio (01530.HK): "On singles' day sales, Mandi topped the charts on multiple platforms."
On November 14th, 3sbio (01530.HK) announced that its subsidiary Zhejiang Sanse Mandy Pharmaceutical Co., Ltd. during the "singles' day sales" campaign in 2024: the main brand Mandy ranked first in OTC brand total payment commodity trade volume (GMV) on the Tmall platform; the core product Mandy hair foam agent of JD Pharmaceutical won the first place in the OTC single product payment GMV list; the main brand Mandy on Douyin Mall won the first place in the medicine and health brand payment GMV list.
Express News | 3Sbio - Since 1 Jan to 14 Nov, CFO Increased Shareholding in Co by Aggregate of 3.0 Mln Ordinary Shares at HKD5.99 per Share
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
